Annual report pursuant to Section 13 and 15(d)

Note 10 - Investment in Macrophage Therapeutics, Inc. (Details Textual)

v3.20.1
Note 10 - Investment in Macrophage Therapeutics, Inc. (Details Textual) - USD ($)
1 Months Ended 6 Months Ended 12 Months Ended
Mar. 11, 2015
Nov. 30, 2018
Jul. 31, 2016
Mar. 31, 2015
May 31, 2016
Dec. 31, 2017
Dec. 31, 2015
Dec. 31, 2019
Dec. 31, 2018
Aug. 31, 2018
Preferred Stock, Shares Authorized               5,000,000 5,000,000  
Preferred Stock, Par or Stated Value Per Share               $ 0.001 $ 0.001  
Preferred Stock, Shares Issued, Total               0 0  
Derivative Liability, Total $ 63,000             $ 0 $ 63,000  
Preferred Convertible Stock, Right to Exchange for Common Shares, Minimum Required Proceeds from Initial Public Offering             $ 50,000,000      
Weighted Average Price Common Stock Percentage             80.00%      
Future Common Stock Conversion Share Price             60.00%      
Reclassification of Funds Invested           $ 200,000        
Dr. Michael Goldberg [Member]                    
Convertible Preferred Stock, Percent of Shares Reserved       40.00%            
Dr. Michael Goldberg [Member] | MT [Member]                    
Payments to Acquire Businesses and Interest in Affiliates, Total     $ 200,000              
Resignation Agreement, Subidiary Percentage Ownership After Signing                   5.00%
Resignation Agreement, Shares Issued   925,000                
Resignation Agreement, Shares in Escrow   250,000                
Macrophage Therapeutics [Member]                    
Common Stock Shares Authorized Upon Exercise of Warrants       1,500            
Convertible Preferred Stock Shares Issued Upon Conversion, Per Unit       1            
Common Stock Warrants, Issued Upon Conversion, Per Unit       30            
Macrophage Therapeutics [Member] | Common Stock [Member]                    
Common Stock as Percentage of Common Equity       1.00%            
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 300             300    
Platinum [Member] | MT [Member]                    
Payments to Acquire Businesses and Interest in Affiliates, Total     $ 300,000   $ 200,000          
MT [Member]                    
Convertible Preferred Stock, PIK Coupon, Percentage     10.00%              
Convertible Preferred Stock, Conversion Price, Market Cap     $ 500,000,000              
Convertible Preferred Stock [Member]                    
Preferred Stock, Shares Authorized       50            
Preferred Stock, Par or Stated Value Per Share       $ 50,000            
Cumulative Preferred Stock [Member]                    
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants, Total $ 500,000                  
Issuance of Stock and Warrants for Purchase Agreement, Remaining Amount             $ 2,000,000      
Preferred Stock, Fair Value Put Option             113,000      
Future Common Stock Conversion Denominator, Value             $ 50,000      
Cumulative Preferred Stock [Member] | Macrophage Therapeutics [Member]                    
Preferred Stock, Shares Authorized       50            
Preferred Stock, Shares Issued, Total       10            
Preferred Stock, Redemption Price Per Share             $ 58,320